Femara (Letrozole)

Femara (Letrozole) is a third generation non-steroidal selective aromatase inhibitor. In terms of structure and activity, this drug is similar to Arimidex (Anastrazole), and is prescribed for the same indications. In particular, letrozole is recommended in the treatment of postmenopausal syndrome with estrogen receptor-positive or estrogen receptor-unknown breast cancers. It is commonly used as a second-line drug of choice after unsuccessful therapy with the estrogen receptor antagonist Tamoxifen, although it may be chosen as a first-line drug depending on the circumstances. Male bodybuilders and other athletes have found their own benefit in the use of letrozole, due to its ability to mitigate / eliminate the estrogenic side effects associated with the use of aromatized anabolic-androgenic steroids, such as: gynecomastia, increased body fat,

Letrozole is one of the latest advances in targeting aromatase inhibition. It is currently the most powerful drug in lowering the level of estrogen in the blood, it has a significantly stronger effect compared to non-selective aromatase inhibitors such as Teslac and Cytadren. The dosage of each Femara tablet is 2.5 mg, and according to the product description, this drug has been able to reduce estrogen levels by 78% in clinical trials. The drug, however, appears to often remain highly effective at lower dosages. The leaflet inside the package informs us that in the course of clinical trials, doses of 0.1mg and 0.5mg led to a decrease in estrogen levels by 75% and 78%, respectively, in many patients. However, it is the recommended dose that achieves the desired effect in all patients. Be that as it may, a huge number of people respond just as well to the use of lower dosages.